Compare SKYX & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | SLGL |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 117.8M |
| IPO Year | 2022 | 2018 |
| Metric | SKYX | SLGL |
|---|---|---|
| Price | $1.99 | $39.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 971.4K | 15.3K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,751,118.00 | $18,970,000.00 |
| Revenue This Year | $9.19 | $121.82 |
| Revenue Next Year | $27.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.06 | ★ 62.04 |
| 52 Week Low | $0.88 | $4.02 |
| 52 Week High | $2.57 | $52.26 |
| Indicator | SKYX | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 54.64 |
| Support Level | $2.10 | $38.30 |
| Resistance Level | $2.52 | $44.04 |
| Average True Range (ATR) | 0.17 | 3.60 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 4.07 | 60.95 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.